CRSP CRISPR Therapeutics AG

CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., President of CRISPR Therapeutics, is scheduled to present at two upcoming Investor Conferences in October.

Event: Chardan Gene Therapy ConferenceDate: Tuesday, October 10, 2017 Time: 2:00 PM EDT

Event: Jefferies Gene Technology Investor SummitDate: Thursday, October 12, 2017 Time: 11:10 AM EDT

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts. For more information, please visit http://www.crisprtx.com.

MEDIA CONTACTS:Jennifer PaganelliWCG on behalf of CRISPR+1 347-658-8290 jpaganelli@wcgworld.com

INVESTOR CONTACT:Chris BrinzeyWestwicke Partners for CRISPR+1 339-970-2843 chris.brinzey@westwicke.com